Sunday 19 May 2024
By
main news image

KUALA LUMPUR (Aug 10); BIMB Securities Research has initiated coverage on Hovid Bhd at with a “Hold” rating at 48 sen with a target price of 49 sen and said Hovid is one of Malaysia’s leading pharmaceutical companies producing ethical drugs (generic drugs), dietary supplements and consumer products.

In a note today, the research house said products manufactured are not only marketed locally but also exported to over 50 countries worldwide.

It said the growing world’s population and rising healthcare awareness had given rise to a rapidly expanding healthcare industry.

“This provides Hovid with a solid platform to thrive on.

“We initiate coverage on the stock with a target price of RM0.49 based on the weighted average local peers PER of 15x over FY16 EPS. Initiate with a Hold recommendation,” it said.

      Print
      Text Size
      Share